| |
|
| 1: |
Sylvestre D. |
|
|
Hepatitis C treatment in drug users: perception versus evidence.
Eur J Gastroenterol Hepatol. 2006 Feb;18(2):129-30. No abstract available.
Click here
|
| 2: |
Sylvestre DL. |
|
|
Approaching treatment for hepatitis C virus infection in substance users.
Clin Infect Dis. 2005 Jul 1;41 Suppl 1:S79-82.
Click here
|
| 3: |
Sylvestre DL, Litwin AH, Clements BJ, Gourevitch MN. |
|
|
The impact of barriers to hepatitis C virus treatment in recovering heroin users maintained on methadone.
J Subst Abuse Treat. 2005 Oct;29(3):159-65.
Click here
|
| 4: |
Sylvestre DL. |
|
|
Treating hepatitis C virus infection in active substance users.
Clin Infect Dis. 2005 Apr 15;40 Suppl 5:S321-4.
Click here
|
| 5: |
Sylvestre DL, Loftis JM, Hauser P, Genser S, Cesari H, Borek N, Kresina TF, Seeff L, Francis H. |
|
|
Co-occurring Hepatitis C, substance use, and psychiatric illness: treatment issues and developing integrated models of care.
J Urban Health. 2004 Dec;81(4):719-34.
Click here
|
| 6: |
Sylvestre DL, Clements BJ. |
|
|
The utility of indirect predictors of hepatitis C viremia.
Drug Alcohol Depend. 2004 Apr 9;74(1):15-9.
Click here
|
| 7: |
Sylvestre DL, Disston AR, Bui DP. |
|
|
Vogt-Koyanagi-Harada disease associated with interferon alpha-2b/ribavirin combination therapy.
J Viral Hepat. 2003 Nov;10(6):467-70.
Click here
|
| 8: |
Sylvestre DL. |
|
|
Treating hepatitis C in methadone maintenance patients: an interim analysis.
Drug Alcohol Depend. 2002 Jul 1;67(2):117-23.
Click here |
|
|